Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Immune Globulin (PID) (Mar 2021)

Posted by Matt Breese on Mar 19, 2021

Find me on:

According to our recent payer coverage analysis for immune globulin (PID) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for immune globulin (PID) treatments shows that under the pharmacy benefit, about 54% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Immune Globulin (PID)-1Q2021Data snapshot as of Q1 2021

Trends: Few plans have shifted towards specialty pharmacy procurement for immunoglobulin products. Since CMS allowed a step therapy in Medicare Part B in 2019, many plans implemented a step therapy strategy that includes immunoglobulin therapy.  

To read the full Reality Check on Immune Globulin (PID) treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing